PD1/PD-L1、中性粒细胞弹性蛋白酶、赖氨酰氧化酶在膀胱癌中的表达及其与膀胱癌预后的关系

The expression of PD1/PD-L1, neutrophil elastase and lysyl oxidase in bladder cancer and their relationship with the prognosis of bladder cancer

目的探讨膀胱癌组织中程序性细胞死亡受体1(PD1)、程序性细胞死亡配体1(PD-L1)、中性粒细胞弹性蛋白酶(NE)、赖氨酰氧化酶(LOX)的表达水平及其表达差异与膀胱癌患者临床病理特征和预后的关系。方法选取2018年1月至2020年12月江西省人民医院收治的56例膀胱癌患者的癌组织作为研究对象,并记录患者的复发和死亡情况进行分析研究。采用免疫组织化学染色法检测PD1、PD-L1、NE、LOX的表达情况,分析PD1、PD-L1、NE、LOX与患者的病理特征和预后的关系。结果免疫组化结果显示PD1在肿瘤相关免疫细胞中存在表达(46/56);TNM分期T2-T3期、高级别肿瘤和出现淋巴结转移的患者PD1和PDL-1的表达阳性率均明显升高,差异有统计学意义(P<0.05)。NE与PD1、PDL-1的表达呈正相关(P<0.05);LOX与PD-L1、PDL-1的表达呈正相关(P<0.05)。PD1阳性表达患者3年无进展生存率为58.70%(27/46),PD-L1阳性表达患者3年无进展生存率为43.48%(10/23),不同PD1、PD-L1表达患者的3年无进展生存率比较差异有统计学意义(P<0.05)。结论膀胱癌组织中PD1、PD-L1表达增加可作为膀胱癌患者潜在的预后预测指标,有助于筛选术后复发的高危患者,并为膀胱癌的免疫学治疗提供新靶点。

Objective To investigate the expression levels of programmed cell death receptor 1(PD1),programmed cell death ligand 1(PD-L1),neutrophil elastase(NE)and lysyl oxidase(LOX)in bladder cancer and their relationship with clinicopathologic features and prognosis.Methods Cancer tissues of 56 patients with bladder cancer admitted to Jiangxi Provincial People's Hospital from January 2018 to December 2020 were selected as the study objects.During the follow-up period,recurrence and death of patients were recorded.Immunohistochemical staining was used to detect the expressions of PD1,PD-L1,NE and LOX,and to analyze the relationship between PD1,PD-L1,NE and LOX and the clinicopathologic features and prognosis of patients with bladder cancer.Results Immunohistochemical results showed that PD1 was expressed in tumor-related immune cells(46/56).The positive expression rate of PD1 in tumor tissues of patients with T2-T3 TNM stage was higher than that of patients with Tis-T1 stage,the positive expression rate of PD1 in patients with high-grade tumor was higher than that in patients with low-grade tumor,and the positive expression rate of PD1 in patients with lymph node metastasis was higher than that in patients without metastasis(P<0.05).The positive expression rate of PD-L1 in patients with T2-T3 TNM stage was higher than that in patients with Tis-T1 stage,and the positive expression rate of PD-L1 in patients with lymph node metastasis was higher than that in patients without metastasis(P<0.05).NE was positively correlated with the expression of PD1 and PDL-1(P<0.05).LOX was positively correlated with the expression of PD-L1 and PDL-1(P<0.05).The 3-year progression-free survival rate was 58.70%(27/46)in patients with PD1 positive expression,and 43.48%(10/23)in patients with PD-L1 positive expression.The 3-year progression-free survival rate of patients with different PD1 and PD-L1 expression was significantly different(P<0.05).Conclusion The increased expression of PD1 and PD-L1 in bladder cancer can be used as potential prognostic indicators for patients with bladder cancer,which can help to screen high-risk patients with postoperative recurrence and provide a new target for the immunological treatment of bladder cancer.